Joint Clinical Assessment, JCA
Senaparib (ovarian cancer)
Dossier assessment
Indication:
Maintenance treatment of advanced epithelial high-grade ovarian, fallopian tube or primary peritoneal cancer
Press releases
First EU HTAs with IQWiG involvement launched
The Institute is involved in four oncology drug assessments as an assessor or co-assessor.
Timetable
- 3rd quarter, 2025
- Start
- 3rd quarter, 2026
- voraussichtlicher Abschluss
Project details
- Project no.
- MP-202418
- Report type
- Joint Clinical Assessment, JCA
- Status
- Commission work started
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
This Joint Clinical Assessment (JCA) is being conducted in cooperation with the Slovenian Quality Health Care Agency.
Further background information can be found here: European health technology assessment